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Abstract 
Background: The American College of Obstetrics and Gynecology (ACOG) and Maternal Fetal Medicine (MFM) 
Societies recommended that abnormal cfDNA fetal results should be confirmed by amniocentesis and karyotyping. 
Our results demonstrate that normal cfDNA results inconsistent with high-resolution abnormal ultrasounds should be 
confirmed by karyotyping following a substantial frequency of incorrect cfDNA results.
Methods: Historical review of our ~4,000 signed prenatal karyotypes found ~24% of reported abnormalities would 
not have been detected by cfDNA. Akron Children’s Hospital Cytogenetics Laboratory has completed 28 abnormal 
cfDNA cases among the 112 amniocenteses karyotyped.
Results: Following abnormal cfDNA results our karyotypes confirmed only 60% of the cfDNA results were consistent. 
Our cases found a normal cfDNA test result followed by a 20 weeks anatomical ultrasound detected a false negative 
trisomy 18 cfDNA result. One cfDNA result that reported trisomy 21 in the fetus was confirmed by karyotyping which 
also added an originally undetected balanced reciprocal translocation. Another reported karyotyped case followed 
by a repeated microarray of pure fetal DNA, together revealed one phenotypically normal newborn with a complex 
mosaic karyotype substantially decreasing the newborn’s eventual reproductive fitness. This second case establishes 
the importance of karyotyping the placenta and cord or peripheral blood when inconsistent or mosaic results are 
identified following an abnormal cfDNA result with a normal newborn phenotype without a prenatal karyotype.
Conclusions: These Maternal Fetal Medicine referrals demonstrate that positive NIPT results identify an increased abnormal 
karyotypic frequency as well as a substantial proportion of discordant fetal results. Our results found: (1) a normal NIPT test 
result followed by a 20 week anatomical ultrasound detected a false negative trisomy 18 NIPT result, (2) a substantial 
proportion of abnormal NIPT tests identify chromosomal mosaicism that may or may not be confined to the placenta, 
(3) follow up karyotyping should be completed on the newborn placenta and peripheral blood when the amniocyte 
karyotype does not confirm the NIPT reported abnormality in order to identify ongoing risk of developing mosaic 
symptoms, and (4) karyotyping all high risk fetuses tested by amniocentesis defines the 24% of chromosome abnor-
malities not currently screened by NIPT.
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Background
Interest in circulating cell free DNA fragments began 
when transplacental transmission of fetal cells into the 
maternal circulation was demonstrated by detection of 
fetal erythrocytes [1]. Subsequently, fetal lymphocytes 
were also found in maternal blood [2]. Then a fluores-
cence activated cell sorter (FACS) isolated whole fetal 
cells from maternal circulation [3] including circulating Y 
chromosome carrying fetal cells from a woman who con-
ceived a male fetus eight (8) years earlier [4]. Neverthe-
less, DNA analysis of microdissected intact circulating 
fetal cells identified with a specific fetal antibody cor-
rectly diagnosed five (5) of five (5) fetuses at-risk for three 
(3) different genetic diseases [5].
Other investigators reported the majority of circulat-
ing fetal DNA (cfDNA) in maternal plasma is derived pri-
marily from the trophoblast [6, 7]a. This was selected as a 
preferred source of fetal DNA to be tested because it has 
an average half-life of 16.3 min post-delivery so that lev-
els are undetectable within hours post-partum [8, 9]. This 
cfDNA can be detected reliably in the maternal circula-
tion by 7  weeks gestation and its relative proportion of 
total circulating DNA increases with gestational age [7]. 
Subsequently, a few selected chromosome-specific sites 
were tagged along with control sites, all tags sequenced 
millions of times, and the total frequencies compared to 
normal DNAs to identify whole chromosome aneuploidy 
in the admixed fetal DNA: trisomy when increased and 
monosomy when decreased.
Testing cfDNA is being applied clinically as a nonin-
vasive fetal screening test to identify the most common 
chromosome aneuploidies [10, 11]. Following reports of 
inconsistencies between circulating fetal DNA analysis 
and subsequent karyotypes, the joint American College 
of Obstetrics and Gynecology (ACOG) and The Society 
of Maternal-Fetal Medicine (SMFM) Committee Opin-
ion stated, “A negative cell free fetal DNA test result does 
not ensure an unaffected pregnancy. A patient with a 
positive test result should be referred for genetic coun-
seling and should be offered invasive prenatal diagnosis 
for confirmation of test results” [12].
Bianchi and collaborators have completed multicenter 
studies reporting fetal placental DNA in maternal cir-
culation to be a substantially improved indicator of fetal 
aneuploidy over prior screening [10, 11]. The overall neg-
ative predictive value was 100% (95% confidence interval 
[CI], 99.8–100). The positive predictive value for trisomy 
21 was 45.5% (95% CI, 16.7–76.6) and for trisomy 18, the 
positive predictive value was 40.0% (95% CI, 5.3–85.3) 
[11]. These positive predictive values are consistent with 
our Maternal Fetal Medicine specialists’ submitted sam-
ples (see “Results”).
Placental mosaicism has been reported in 0.8 to >2% 
of viable fetuses studied by chorionic villus sampling at 
10–12  weeks gestation with a cytogenetic abnormality 
in the placenta [6, 13–18]. In one study of 11,200 cases¸ 
available follow up found 20% of placental mosaic cases 
were also in fetal tissues [14]. This same study confirmed 
rates for fetal mosaicism between 7.6% for autosomal tri-
somy to 77.8% for a marker chromosome [14]. Intrauter-
ine growth restriction (IUGR) and small for gestational 
age (SGA) infants in about 10% of pregnancies are both 
associated with an increased risk for perinatal morbid-
ity and mortality. Chromosomal mosaicism confined 
to extra embryonic tissues (CPM) has been observed in 
over 20% of pregnancies with idiopathic IUGR [6, 7].
Discordant placental DNA in maternal circulation, 
ultrasound, and karyotypes in this study emphasize the 
importance of invasive fetal testing and targeted follow 
up analysis of term placenta and newborn blood. Of the 
six cases with discordant cfDNA results, one case with an 
abnormal fetal ultrasound following a normal reported 
circulating placental DNA in maternal blood revealed tri-
somy 18 in all fetal amniocytes (Table 1, case 1). Another 
four cases had discordant trisomy 21, monosomy X, and 
trisomy 18 results (Table  1, cases 2–5). A molecularly 
balanced translocation detected by follow up karyotyping 
a trisomy 21 fetal cfDNA result (Table 1, case 6) reflects 
the limitations of testing only the most frequent chro-
mosome abnormalities by NIPT. Together these cases 
emphasize the importance of counseling and confirma-
tion of inconsistent circulating placental DNA and ultra-
sound results by ongoing testing in amniocytes, placenta 
and/or newborn blood.
Methods
Prior to offering one of the circulating fetal DNA screen-
ing tests to pregnant mothers, patients referred to our 
regional Maternal Fetal Medicine specialists are counse-
led that these NIPT tests for circulating placental DNA in 
maternal circulation are screening tests and as such are 
not entirely diagnostic. Of the four testing laboratories 
that originally analyzed fetal chromosome aneuploidy 
in cfDNA, maternal blood samples were sent to either: 
(1) Sequenom testing with MaterniT21, or (2) Ariosa 
Diagnostics testing with Harmony at Integrated Genet-
ics (Table 1b). Following a positive screening test result, 
amniocentesis was offered to all the cases with an abnor-
mal fetal result in circulating placental DNA test result 
according to our initial protocol and confirmed by the 
ACOG recommended protocol [12]. Given a gestational 
age of 27  weeks of a fetus after testing positive for tri-
somy 18 by NIPT, this single fetal case was retested by a 
second NIPT test that gave a normal result.
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FISH analysis of direct amniocytes was completed on 
fixed nuclei hybridized to probes for chromosomes 13, 
18, 21, X, and Y according to standard Vysis protocols 
(Abbott). Karyotyping was completed on amniocytes, 
placental biopsies, and/or newborn blood samples by tis-
sue culture, trypsin digestion and cell harvesting, hypo-
tonic swelling, fixing, and slide preparation according 
to the standard protocols. Metaphase karyotypes were 
banded by trypsin digestion followed by Wright’s stain-
ing and G-banded analysis [Akron Children’s Hospital 
Cytogenetic Laboratory].
Term placentas from positive testing fetuses were 
placed into medium, stored cold, and transported at 
4°C prior to analysis. Pathologists Dr. Kimberly Eickholt 
or Dr. Dimitris Agamanolis obtained biopsied samples 
of villous rich tissue from each placenta. According to 
our placental Products of Conception (POC) protocol, 
cytogenetic technologists further dissected the chori-
onic villi from the maternal deciduas, disbursed the cells 
with collagenase, and seeded the cells in two independ-
ent flasks. The dissected chorionic villous sampled (CVS) 
cells that grew in two flasks were karyotyped. In addition, 
an aliquot of collagen digested villous cells were pre-
pared in hypotonic and fixed for possible additional FISH 
analysis. Chorionic villous cells that grew in culture were 
karyotyped according to standard protocols.
The placenta from the circulating placental DNA test-
ing positive for Turner Syndrome (45,X) (Table 1, case 5) 
was biopsied in four places and tested as two composite 
samples, paraffin embedded, and the cells removed as a 
core, deparaffinized, digested overnight in collagenase 
to disburse the cells, the cells fixed, and attached to the 
surface of a microscope slide. FISH analysis proceeded by 
hybridization to chromosome X labeled with spectrum 
green, Y labeled with spectrum orange, and 18 labeled 
with spectrum aqua (Vysis) which were scored and cap-
tured independently for each nucleus.
Akron Children’s Hospital Internal Review Board 
Chairman Dr. Robert Novak discussed and assured com-
pliance with required clinical and research applications 
of these results at each step in the process. The patients’ 
results reported in detail have a signed permission to 
publish these data.
Results
Amniocentesis summary beginning with first discordant 
NIPT result
One hundred three (103) amniocentesis samples 
(Table 2) have been karyotyped by our Akron Children’s 
Hospital Cytogenetics Laboratory beginning with the 
first sample for which the karyotype was inconsistent 
with the NIPT result (NIPT-noninvasive prenatal test-
ing; cfDNA-circulating fetal DNA). Of these fetuses, 53 
were sonographically abnormal (Table  2). Fifteen (15) 
of 97 were abnormal by NIPT including 9 confirmed 
by karyotyping, while the remaining 6 had false posi-
tive, inconsistent, or mosaic results and one (1) with an 
abnormal ultrasound had a false negative trisomy 18 
result by NIPT (six selected cases listed in Table 1). This 
experience includes ~60% confirmed abnormal NIPT 
Table 1 Six listed discordant NIPT results (case numbers 1–6) among  the nine confirmed abnormal NIPT results (case 
numbers 7–15)
Case number NIPT Karyotype Phenotype
1 2 × 21,13,18, X
MaterniT21










Term Placenta: 46,XY Normal newborn:
3 Trisomy 21 >99% harmony Amniocentesis: 46,XY[18]/Fish[50] Normal newborn
Blood: 46,XY






6 Trisomy 21 Amniocentesis: 47,XY,t(5;9)(p15;q12)+21
Microarray: trisomy 21
Balanced t(5;9) not detected
7–11 Trisomy 18 47,X_, +18
12–15 Trisomy 21 47,X_, +12
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fetal test results. These confirmed results are consist-
ent with the positive predictive test value of 40% for 
trisomy 18 reported for a very large tested series of preg-
nant patients (Bianchi et  al. 2014). The correctly identi-
fied chromosome abnormalities include five trisomy 18 
fetuses and four trisomy 21 fetuses. The discordant NIPT 
results involve trisomy 18, trisomy 21, or monosomy X 
(Table 1). No fetus was reported to have originated from 
in vitro fertilization.
Trisomy 18 fetal results
Five NIPT results reflecting fetal trisomy 18 were con-
firmed by follow up karyotypes of amniocytes. In con-
trast, one fetus was reported in an early test to be normal 
for all chromosomes tested by MaterniT21 including 
chromosome 18 with a specificity of 99.6% and a CI 
99.2–99.6% for chromosome 18 (Table  1, case 1). The 
Maternal Fetal Medicine specialist followed this result 
with an ultrasound that found multiple abnormalities 
including left sided diaphragmatic hernia with hernia-
tion of bowel and liver, echogenic kidneys, and bilateral 
hydronephrosis. When amniocentesis was offered and 
completed based upon an abnormal ultrasound, a tri-
somy 18 fetal karyotype was found in all 28 of 28 amni-
ocytes examined (Fig.  1). More than half of our Ohio 
patients elect to carry a trisomy 18 fetus. Intensive care 
units at 24 immediately surrounding hospitals in our area 
have adopted a protocol to only provide comfort care to 
trisomy 18 fetuses surviving delivery to avoid protracted 
ICU stays. Given this information about ICU protocols, 
this mother elected to continue the pregnancy, delivered 
at her local hospital, and then held the newborn for the 
40 min it survived after birth. This case emphasizes the 
importance of further testing to optimize ongoing care 
when an abnormal fetal ultrasound is observed following 
a normal NIPT result.
Another patient was reported to be carrying a 9 week 
3 day gestation fetus “Positive for Trisomy 18” with a sen-
sitivity of 99.9% and a confidence interval of 92.4–100% 
by MaterniT21 (Table 1, case 2). This report continued, 
“DNA test results do not provide a definitive genetic 
risk in all individuals… (and) does not replace the accu-
racy and precision of prenatal diagnosis… (This patient) 
should be referred for genetic counseling and offered 
invasive prenatal diagnosis for confirmation of test 
results”. The obstetrician ordered the NIPT test repeated 
at 23 weeks gestation and this result was reported to be 
“normal for chromosome 21, 18, and 13 material” with a 
specificity of 99.6% and a confidence of 99.2–99.8%.” The 
lab director wrote, “Repeat testing was negative for tri-
somy 18 which was originally reported as positive… Sam-
ple identity testing confirmed that original and redrawn 
sample were from the same individual. A biological inter-
ference is suspected but this discrepancy remains unre-
solved”. The patient elected to continue the pregnancy 
and delivered a healthy, normal male. Four biopsies were 
obtained from the “Mature placenta with patchy mild vil-
lous edema and chorangiosis”. Karyotyping biopsies from 
4 biopsies of dissected chorionic villi grown in two cul-
tures found 30 of 30 cells with normal male karyotypes 
(Fig. 2).
Trisomy 21 fetal results
Four (4) NIPT results indicating each fetus had trisomy 
21 were confirmed by follow up amniocyte karyotypes. 
The fifth patient was reported to be carrying a 16 week 
5  day fetus positive for Trisomy 21 by Ariosa (Table  1, 
case 3). Subsequent amniocentesis found 66 of 66 meta-
phase cells with a normal two copies of chromosome 21 
by both FISH and karyotyping. The newborn phenotype 
was normal (Table 1, case 3).
Another patient (Table 1, case 4) reported herein tested 
positive for trisomy 21 by circulating placental DNA 
with the report stating the likelihood of this trisomy 21 
result being correct was “validated at 100%” [19; Ariosa 
Diagnostics]. According to ACOG Committee Guide-
lines, all cases of circulating placental DNA (cfDNA) that 
have tested positive for a fetal chromosome abnormality 
are counseled that the positive result was obtained by a 
screening test and that no irreversible decision should be 
made prior to completing a subsequent amniocentesis. 
According to the recommendations of ACOG, Ariosa, 
and Akron Children’s Maternal Fetal Medicine Division, 
a follow up amniocentesis was offered during counseling. 
The mother elected to complete amniocentesis that 
found 90% of 50 uncultured interphase amniocyte nuclei 
with normal chromosome 13 and 21 patterns and no 
nuclei with a trisomy 21 pattern. Subsequent karyotypes 
of cultured cells found 28 of 28 amniocytes with normal 
Table 2 Additional indications for  all karyotyped amnio-
centeses
Completed while testing the NIPT cases (Table 1).
Total number Indication
53 Abnormal ultrasounds:
 Including heart defects (14); IUGR (4); echogenic  
bowel (4)
 spina bifida (3), skeletal abnormalities (2) choriod  
plexus cyst
 oligohydramnios; cystic hygroma
26 Increased marker screening risk: 2 atypical abnormal 
karyotypes
12 Advanced maternal age
9 Family history: genetic disease including metabolic, 
chromosomal, Rh
2 Other
1 Parvovirus exposure: 46,XY karyotype
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46,XY male karyotypes. A follow up Level II ultrasound 
found the fetus did not have any visualized phenotypic 
abnormalities or soft markers of aneuploidy. The patient 
elected to continue the pregnancy.
Because placental mosaicism was previously detected 
in circulating placental DNA [14] prior to delivery, this 
fetus’ term placenta was requested along with a new-
born blood sample. This G4P2 fetus was subsequently 
delivered by C-section at 38  weeks gestation with sym-
metric growth restriction but with no trisomy 21 asso-
ciated phenotype. The requested fresh placenta stored 
cold in culture medium was transported to our cytoge-
netics laboratory for follow up analysis according to 
our standard POC protocol (Figs.  3, 4). A pathologist 
biopsied the placenta in four locations and the biopsied 
chorionic villi were further dissected to an estimated 
95% purity, digested in collagenase, and cultured. CVS 
karyotypes from both of the two successfully cultured 
biopsies included eighteen (18) 47,XY, +21 cells and two 
(2) 46,XY cellsc. These results define the origin of the 
abnormal trisomy 21 circulating fetal DNA result and 
explain the newborn’s symmetric growth restriction.
Given ~20% of reported placental mosaicism is also 
found in the fetus [14], a newborn blood sample from 
this 6   day old was requested and karyotyped as a sec-
ond tissue sample. All 20 of 20 cells were normal 46,XY 
male. Together with the original amniocyte karyotype of 
46,XY normal male in 28 of 28 amniocytes, these results 
support the interpretation that the 47,XY, +21 cells were 
confined to the placentac emphasizing the importance of 
karyotyping amniocytes and newborn cord or peripheral 
blood lymphocytes in phenotypically normal newborns. 
Together all these results support the interpretation that 
the abnormal trisomy 21 karyotype was confined to the 
placenta and the fetus has a normal constitutional karyo-
type (Fig. 3). Following this counseling and testing saga, 
this patient expressed her gratitude for the thorough 
counseling and testing she had received throughout her 
pregnancy, emphasizing the importance of supportive 
patient care.
Fig. 1 Trisomy 18 fetal amniocytes from a fetus normal by NIPT.
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A mosaic trisomy 21/tetrasomy 21/normal karyotype 
confined to the placenta was reported was found in a 
CVS sample in the 1990s that may have been related to 
the tetrasomy 21. Other mosaic placentally confined 
chromosome aneuploidies were reported in 0.8 to >2% of 
viable fetuses. Taken together, these results are consistent 
with previously reported confined placental mosaicism 
associated with IUGR [13–15]. The biopsied placental 
karyotypes also explain the results of Ariosa’s cfDNA 
test indicating a fetal trisomy 21 genotype and further 
emphasize the importance of an ACOG recommended 
follow up karyotype on amniocytes [12] plus our new-
born blood karyotype to determine whether both these 
tissues have entirely normal chromosomes. Standard lab-
oratory protocols for POC analysis that culture dissected 
chorionic villi stored at 4°C up to 5 days typically result 
in a fetal karyotype >90% of the time while placental villi 
kept at room temperature have also remained viable for 
3  days. Subsequent FISH analysis of paraffin embed-
ded nuclei added by Pathologists identified the common 
chromosome aneuploidies in most of the remaining cases 
that failed to grow in culture [20, 21]. Our laboratory 
protocol accompanying this report (Figs.  3, 4) could be 
adopted readily into the College of American Patholo-
gists (CAP) guidelines.
Monosomy X results
Case 5 (Table  1) is a fetus that presented at 27  weeks 
6  days with intrauterine growth retardation. Given the 
fetus’ late gestational age, NIPT was selected as the most 
appropriate test and a maternal blood sample was sub-
mitted to Ariosa. The 27.3% of circulating fetal DNA 
indicated the fetal karyotype was monosomy X with a 
probability greater than 99/100 (99%). The patient car-
ried the fetus. At birth the fetus was small for gestational 
age with a sacral dimple, jaundice, and poor feeding 
that resolved but was otherwise phenotypically normal. 
The 6  days infant was discharged home. A thorough 
physical exam by a geneticist for 30 characteristics at 
2 months and again at 3 months revealed no discernible 
abnormalities.
Karyotypes and FISH analysis of newborn blood found 
45,X[9]/46,X,dup(X)(q13q21.3)[41] (Fig.  5) with a single 
X inactive specific transcript (XIST) gene locus in band 
Fig. 2 Normal male term placental karyotype. Trisomy 18 by NIPT.
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Fig. 3 a Peripheral blood from a newborn with trisomy 21 by NIPT. b Placenta from newborn reported as trisomy 21 by NIPT.
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Fig. 4 Protocol for further fetal testing following a report of abnormal placental DNA in maternal circulation.
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Xq13 by FISH. Microarray analysis confirmed the new-
born’s 45,X mosaic cell line in a small fraction of the cells 
and a second more frequent cell line with a duplication 
on the X chromosome long arm dup(X)(q21.1q21.33) 
spanning from 83,317,750 to >96,924,899  bp (Fig.  6). 
This duplication resulted in 3 total chromosome X long 
arm region copies given 1 copy on the normal X chro-
mosome and two copies on the X with the duplication. 
The microarray X chromosome plot (Fig.  6) also illus-
trates that cells with 45,X comprise ~15 to >20% of the 
total number of cells in this independent sample. These 
mosaic 45, X cells explain the monosomy X result in a 
portion of placental DNA tested in maternal blood which 
is consistent with IUGR at 27 weeks. FISH analysis of the 
parents’ blood had normal patterns indicating the new-
born’s chromosome abnormalities are de novo.
Fig. 5 GTW-banded karyotypes of monosomy X and Xq duplication on patient 3. The third case had a mosaic karyotype with Monosomy X in 9 
cells and an X chromosome with a duplication of the long arm 45,X[9]/46,X,dup(X)(q13q22.1) [41]. The G-banded X chromosomes in 9 pf 50 cells 
are shown for the 45,X cell line (top), and 4 cells of the second cell line with the duplicated chromosome regions indicated on the normal idiogram 
to the left (bottom). The normal X chromosome is illustrated for five metaphase cells to the left of the X chromosome with the long arm duplica-
tion to the right of it. The arrows are drawn to the Xq21.1 and Xq21.2 bands. [Illustration courtesy of James Malone, Supervisor, Akron Children’s 
Cytogenetic Laboratory].
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Uniparental disomy was also identified by polymorphic 
microarray analysis in this newborn’s DNA from Xq21.33 
to Xq28. This is most likely explained by unequal X long 
arm recombination in parental Meiosis I that resulted in 
a duplication followed by cosegregation of the normal 
and duplicated X chromatids to the same gamete. Given 
no clearly defined paternal or maternal imprinted gene 
regions on the X chromosome, this finding below the 
duplicated chromosome region on dup(X)(q21.1q21.3) 
does not modify patient prognosis. Given a single XIST 
gene locus on both the patient’s normal and derivative 
X chromosomes without an extra XIST copy by FISH, 
this copy number minimally modify a female newborn’s 
phenotype provided the duplication breakpoints did not 
result in an X-linked dominant genetic disease. This is in 
contrast to an X chromosome with two XIST genes that 
typically inactivate nearly all X chromosome genes to 
mimic a Turner phenotype [22]. However, this patient’s 
long term prognosis is significantly modified when she 
reaches reproductive age with a substantially increased 
Fig. 6 X chromosome microarray result on patient 3. The primary result from top to bottom is two copies of the X chromosome in ~120 Mb of 
the X chromosome in ~85–90% of the cells and one copy of the X chromosome [45,X] in ~18% of the cells (lower triangle). One extra copy of the X 
chromosome region [46,X,dup(X)(q21.1q21.3)] in ~82% of cells (upper triangle). FISH with a duplicated region confirmed that the cells with a single 
X chromosome contained only the normal X and each X chromosome had a single XIST gene in band Xq13. The horizontal axis is drawn and the 
result plotted as the natural logarithm of the data to ensure quantification of multiple copies in the same cell occasionally seen as amplified copies. 
The image is provided by Daniel Pineda-Alvarez M.D., FACMG, Associate Microarray Director, GeneDx. The difference in the GTW banded chromo-
some breakpoints is based upon lower resolution FISH analysis using a limited number of chromosome probes and measuring the distance on 
idiograms that are not based upon measured band location.
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risk of chromosomally abnormal gametes derived 
from the duplicated chromosome region resulting in 
a substantially increased risk of miscarriage. This case 
emphasizes the importance of karyotyping a phenotypi-
cally normal appearing newborn after it tests abnormal 
by NIPT (Figs. 7, 8).
Fig. 7 From Fetal Case 5. Left DAPI stained karyotypes of normal and Xq duplication chromosome centromeres labeled green and with control 
chromosome 18 centromere labeled aqua.
Fig. 8 Case 5. Fetal DAPI banded karyotypes of normal and Xq duplication [add(X)] chromosome centromeres labeled green and the control chro-
mosome 18 centromere labeled aqua.
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Trisomy 21 and a balanced reciprocal translocation
One of five trisomy 21 patients tested by NIPT and con-
firmed to have trisomy 21 also had a balanced reciprocal 
translocation characterized by G-banded karyotyping: 
46, XY, t(5;10)(p15;q12). (Table  1, case 6; Figs.  9, 10) A 
follow up microarray was completed that confirmed the 
translocation is submicroscopically balanced because a 
submicroscopic deletion or duplication at the translo-
cation breakpoint could not be detected and would not 
have been detected by a microarray alone. This specific 
case emphasizes that following abnormal NIPT results by 
karyotyping also detects any tested additional chromo-
some abnormalities not currently screened by NIPT.
Discussion
These cases illustrate the following principles: (1) Nonin-
vasive prenatal testing is enhanced by thorough ongoing 
patient counseling. (2) Abnormal ultrasounds with a rec-
ognizable genetic etiology should be offered an invasive 
procedure to test for a genetic abnormality even when 
placental DNA screening was normal. (3) The reported 
frequencies of abnormal circulating placental DNAs is 
lower than the reported ~1.5% mosaic CVS frequency, 
suggesting that many chromosomally mosaic placen-
tas are not detected by NIPT. (4) Given that ~20% of 
reported placental mosaicism is also detectable in the 
fetus [14], amniocyte karyotypes should follow any prior 
abnormal circulating placental DNA result and karyo-
typing newborn cord or peripheral blood should be con-
sidered when the amniocyte karyotype and/or newborn 
phenotype is normal [5]. Because circulating placental 
DNA is more accurate than previous fetal screening tests 
in experienced laboratories, the frequencies of abnormal 
NIPT results have increased ~10-fold when selected high 
risk patients are referred to more specialized Obstetri-
cians and Maternal Fetal Medicine Clinics.
Ultrasounds are an important screening adjunct
Our initial reported karyotyped case demonstrated that 
fetuses with abnormal ultrasounds and a recognizable 
etiology should be offered an invasive diagnostic pro-
cedure to test for the most likely genetic origin of the 
phenotype. Improved ultrasound devices, training, and 
experience enable obstetricians to characterize abnormal 
Fig. 9 Case 6 karyotype.
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and normal fetal phenotypes in spite of an erroneous test 
result. Thus judiciously interpreted ultrasounds provide 
an important check to any laboratory test result.
Enrichment of inconsistent placental results in reference 
centers
Placental mosaicism has an overall frequency of ~1.5% 
in five large chorionic villus sample studies [6, 13–17]. 
Among these mosaic cases that may be detected by test-
ing circulating placental DNA, ~80% are confined to the 
placenta while ~20% are also found in the fetus. Because 
a normal amniocentesis karyotype following an abnor-
mal circulating placental DNA result only tests one 
fetal tissue source, additional assurance that this result 
reflects the fetal status could be obtained by completing a 
20 weeks anatomic ultrasound for phenotypic abnormal-
ity and IUGR. Among our 103 amniocenteses completed 
with 15 previously tested by NIPT, 9 of 15 were con-
firmed to have abnormal karyotypes and 7 of 15 had dis-
cordant karyotypes reflecting a substantial improvement 
over prior tests. Testing polymorphic sites that regularly 
differ in paternal DNA polymorphisms is anticipated to 
further increase NIPT reliability.
One of our trisomy 21 NIPT results (Table  1, case 4) 
followed by a normal fetal karyotype and a mosaic tri-
somy 21 placenta, indicates that large future studies that 
include fetal placental analysis when discrepant results 
are found will determine the true frequency of discord-
ant NIPT results. Furthermore, the reported frequency of 
0.1% false positive results in all risk populations by expe-
rienced laboratories [9] predicts that the 1.5% of mosaic 
fetal placentas have not all been detected failing to char-
acterize some cases of IUGR.
Future approaches
A subsequent more informative fetal screening test with 
substantially increased reliability based upon the many 
tested sites at each targeted chromosome region would 
be completed by adding the 54 sites that would have 
detected all unbalanced fetal chromosome rearrange-
ments among our 938 abnormal karyotypes (Fig. 11; [21, 
23]). In contrast, the 2,500,000 genomewide microarrays 
[21] would not have detected any reported additional 
cases in the most recent 12  years [11, 24]. Even when 
smaller targeted aneuploid sites are tested, the genomic 
region will have many informative polymorphic sites to 
Fig. 10 Case 6. Right DAPI stained interphase nuclei with three chromosome 21 centromeres labeled in red and green and two chromosome 21 
centromeres labeled with control chromosome 13 centromere probe labeled in green. This confirms that three copies of the Down Syndrome criti-
cal region are found in each nucleus and therefore the above karyotype will result in Down Syndrome. Left The normal Y chromosome centromere 
is labeled in red, the normal X chromosome centromere in green, and to different since normal chromosome 18 centromeres labeled in aqua reflect 
a normally variable difference in the number of centromeric repeats.
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query to meet the current standards applied to whole 
chromosome testing. Another goal would screen de novo 
submicroscopic chromosomal aneuploidies in placental 
DNA [11, 25, 26]. The protocol requiring follow up analy-
sis of all abnormal results will be prudent for all ongoing 
and pending karyotype applications.
Thorough analysis optimizes patient care
Rapid DNA testing has enabled new test applications at 
an unprecedented rate. Reliably predicting all the con-
sequences of each application is not always possible. 
Nevertheless, given the sophisticated data presented by 
these enabling technologies, a thorough understanding 
of all existing reported data assists in optimizing ongo-
ing interpretation and intervention. Ongoing patient 
counseling optimizes outcomes. ACOG supports a rec-
ommendation to compile and report all inconsistent 
results between abnormal circulating fetal DNA and nor-
mal fetal cells. Our results further emphasize the impor-
tance of (1) completing invasive prenatal diagnosis of all 
abnormal ultrasounds in the face of existing normal pla-
cental DNA results, and (2) completing results on new-
born bloods to either confirm a normal invasive prenatal 
karyotype is not mosaic in another tissue or to test the 
newborn karyotype when a prenatal karyotype was not 
obtained following an abnormal ultrasound.
Conclusion
This manuscript (1) reports and explains the predicted 
increased frequency of discordant placental DNA results 
to fetal karyotypes at Maternal Fetal Medicine referral 
centers, (2) demonstrates the importance of follow up 
ultrasound with normal NIPT results, (3) karyotyping 
phenotypically normal newborns with abnormal NIPT 
results, (4) ongoing thorough counseling, and (5) pro-
vides our laboratory protocol for follow up analysis of 
placenta along with cord or peripheral newborn blood 
(Additional file 1).
Our 103 amniocenteses completed for all indications 
since the first case of inconsistent results between cir-
culating trophoblastic DNA, ultrasound, and amniocyte 
karyotypes include 6 cases of inconsistent results plus 8 
cases of abnormal NIPT results confirmed by karyotyp-
ing. These positive abnormal frequencies of circulating 
trophoblastic DNAs ~15% (15 of 103) are attributed to 
the enrichment of positive testing trophoblastic cases 
referred to Maternal Fetal Medicine specialists. Our last 
case correctly reported monosomy X in a mosaic pla-
centa, but found a different major chromosome abnor-
mality in a phenotypically normal newborn predicting 
Fig. 11 26 Abnormal karyotypic categories detected at 54 sites listed 
by decreasing severity. (Reprinted from Lebo and Tonk [26]).
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high risk of major unanticipated difficulties at reproduc-
tive age. Presented cases highlight our attention to (1) 
the abnormal subsequent ultrasound following a normal 
circulating trophoblastic DNA (cfDNA) result on a tri-
somy 18 fetus, (2) the substantial proportion of abnormal 
mosaic placental karyotypes among all abnormal cfDNA 
results that may or may not be identified in the fetus, 
(3) the correct fetal information in advance of patient 
care even when the patient elects to carry an abnormal 
fetus, and (4) one false positive cfDNA result followed by 
amniocentesis that resulted in complications necessitating 
extended maternal hospitalization. Together these cases 
emphasize the significance of pretest counseling, follow-
ing up NIPT results with targeted ultrasound and amni-
ocentesis, and karyotyping the placenta and cord blood 
given inconsistent or mosaic results.
Endnotes
aFetal DNA circulating in maternal blood originating 
in the placenta is referenced as the target of Noninvasive 
Prenatal Testing (NIPT) in the remainder of this study.
bLicensed tests initially offered commercially, 2013:
A. The Harmony Prenatal Test™ (Ariosa Diagnostics, 
San Jose, California), employs directed analysis of 
cell-free DNA fragments. This test selected regions 
(DANSR™) with a proprietary algorithm, FORTE™, 
to selectively analyze cell-free DNA in maternal 
blood for trisomy 21, 18 and 13.
B. The Verifi™ Prenatal Test (Verinata Health Inc., 
Redwood City, CA), utilizes massively parallel DNA 
sequencing to identify an increased representation of 
chromosomes 21, 18, and13. Verinata Health Inc also 
offers testing for Monosomy X (Turner Syndrome) as 
an additional option to the verifi(TM) prenatal test;
C. MaterniT21™ Plus Test (Sequenom Center for 
Molecular Medicine, Grand Rapids, MI), utilizes 
massively parallel DNA sequencing to identify tri-
somy of chromosomes 21, 18, 13, 16, and 22; 22q 
deletion syndrome (DiGeorge), 5p (Cri-du-chat syn-
drome), 15q (Prader-Willi/Angelman syndromes), 
1p36 deletion syndrome.
D. Natera, Inc. 201 Industrial Road, Suite 410, San Car-
los, CA 94070, (650) 249-9090] provides the Pano-
rama prenatal test based upon single nucleotide poly-
morphisms.
cThe 4 CVS samples were further analyzed by FISH for 
chromosome 21 and chromosome 13 copy number. Fol-
lowing collagenase digestion of dissected villous cells, 
hypotonic, and immediate fixation, FISH analysis found 
50 of 50 cells with two copies of the chromosome 13q 
probe but 32% of these nuclei with three copies of the 
21q probe [AneuVysion, Abbot]. The other three biop-
sied CVS samples had 68, 40, and 80% trisomy 21 nuclei 
among 25 scored cells each while all nuclei had two cop-
ies of the control chromosome 13 locus.
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